MRNA
Moderna Rallies on Five-Year Cancer Vaccine Data, Pivots Away from Vaccine Development
Moderna and Merck announced positive five-year follow-up data for their personalized mRNA cancer vaccine combined with Keytruda, showing it maintained a 49%...
